Tripterygium wilfordii Hook. f. and Xinfeng Capsule in Rheumatoid Arthritis: A Review of Clinical Evidence, Molecular Mechanisms, and Translational Perspectives - Report - MDSpire
Advertisement
Tripterygium wilfordii Hook. f. and Xinfeng Capsule in Rheumatoid Arthritis: A Review of Clinical Evidence, Molecular Mechanisms, and Translational Perspectives
Clinical Report: Efficacy and Mechanisms of Tripterygium wilfordii in RA
Overview
This comprehensive review evaluates the efficacy and mechanisms of Tripterygium wilfordii Hook. f. (TWHf) and Xinfeng Capsule (XFC) in managing rheumatoid arthritis (RA). Clinical evidence suggests these treatments may improve disease activity and inflammatory markers, although challenges such as toxicity and the need for high-quality trials remain.
Background
Rheumatoid arthritis (RA) is a prevalent autoimmune disease characterized by joint inflammation and destruction, affecting approximately 1% of the global population. Traditional treatments primarily involve disease-modifying antirheumatic drugs (DMARDs), but the integration of herbal medicines like TWHf is gaining attention. Understanding the efficacy and safety of TWHf and its derivatives is crucial for optimizing RA management.
Data Highlights
No numerical data available in the source material.
Key Findings
TWHf has been used in traditional medicine for RA treatment, showing potential efficacy.
Preclinical studies indicate TWHf regulates key inflammatory pathways, including NF-κB and PI3K/AKT/mTOR.
XFC demonstrates broader regulatory effects compared to isolated TWHf monomers.
Clinical studies suggest TWHf preparations can improve disease activity and inflammatory markers.
Challenges include toxicity, lack of high-quality multicenter RCTs, and insufficient standardization.
Future research should focus on standardized formulations and biomarker-guided applications.
Clinical Implications
Clinicians should consider the potential benefits of TWHf and XFC in RA management while remaining aware of the associated risks and the need for further research. Standardization and safety monitoring are essential for integrating these treatments into clinical practice.
Conclusion
TWHf and XFC present promising options for RA management, but further rigorous clinical evaluation is necessary to establish their safety and efficacy in standard treatment protocols.
Higher oxidative balance was associated with lower mortality, while greater systemic inflammation was linked to increased risk in a US cohort of patients with rheumatoid arthritis.
The agency outlined early regulatory actions supporting nonanimal methods, including draft guidance, artificial intelligence tools, and expanded use of human-relevant data models.
